<DOC>
	<DOCNO>NCT01999361</DOCNO>
	<brief_summary>This single-center , prospective , open label study islet transplant recipient complete islet graft rejection/loss , define stimulate c-peptide ≤0.3 ng/mL .</brief_summary>
	<brief_title>Prevention de Novo Allosensitization Islet Transplant Recipients Following Complete Graft Loss</brief_title>
	<detailed_description>After complete islet graft loss determine , patient 's maintenance immunosuppression ( i.e . sirolimus tacrolimus ) discontinue place Myfortic® monotherapy 2 year thereafter . After completion two year Myfortic® maintenance monotherapy , wean subject monitor subsequent twelve month , appearance sensitization use panel reactive antibody ( PRA ) level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Male female patient age 1870 year age . 2 . Ability provide write informed consent . 3 . Mentally stable able comply procedure study protocol . 4 . Any subject currently prescribe immunosuppressive medication discontinuation immunosuppressive medication indicate per current protocol islet transplantation . 5 . History least one islet transplant . 6 . Stimulated Cpeptide &lt; 0.3 ng/ml . 1 . Known history untreated severe hyperlipidemia , obesity , refractory hypertension 2 . For female participant : Positive pregnancy test presently breastfeed . 3 . History active infection include hepatitis B , hepatitis C , HIV , TB . 4 . Any history malignancy except completely resect squamous basal skin cell carcinoma . 5 . Known active alcohol substance abuse . 6 . Severe coexist history cardiac disease , characterize history one condition : recent myocardial infarction ( within past 6 month ) , evidence ischemia functional cardiac exam within last year , leave ventricular ejection fraction &lt; 30 % . 7 . History persistent elevation liver function test . SGOT ( AST ) , SGPT ( ALT ) , alkaline phosphatase total bilirubin , value &gt; 1.5 time normal upper limit exclude patient . 8 . Evidence intercurrent infection . 9 . Active peptic ulcer disease 10 . History nonadherence prescribe regimen include immunosuppression . 11 . PRA ≥ 50 % evidence significant sensitization determine discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>